File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Phase Iib Extended-Treatment Trial of Telbivudine (LdT) Vs Lamivudine Vs Combination Treatment in Hepatitis B Patients: Two-Year Results

TitlePhase Iib Extended-Treatment Trial of Telbivudine (LdT) Vs Lamivudine Vs Combination Treatment in Hepatitis B Patients: Two-Year Results
Authors
Issue Date2005
PublisherElsevier Inc.
Citation
Digestive Disease Week, Chicago, IL, 14-19 May 2005. In Gastroenterology, 2005, v. 128 n. 4 S2, p. A-692 How to Cite?
AbstractBackground: In a 1-year Phase IIb trial, telbivudine (LdT) treatment produced significantly greater antiviral effects and ALT normalization than standard lamivudine monotherapy in HBeAg-positive patients with chronic hepatitis B (Lai AASLD2003). The present follow-on study was designed to gain longer-term data on the comparative efficacy and safety of LdT vs lamivudine in patients who completed the previous trial. Methods: Patients (pts) completing the earlier trial were offered continuing treatment according to their previous treatment type: (a) pts previously treated with lamivudine continued on lamivudine (100 mg/d); (b) pts previously treated with LdT monotherapy (400 or 600 mg/d) continued on LdT 600 mg/d; and (c) pts previously treated with a combination treatment (LdT 400 or 600 mg/d plus lamivudine) continued on combination treatment (LdT 600 mg/d plus lamivudine 100 mg/d). Here we report efficacy and safety observations after 1 year of additional treatment, comprising 2 years of continuous treatment with these 3 types of anti-HBV treatment. Results: 90 of 99 pts (90%) who completed the previous study enrolled in this extension study. Overall tolerance of all 3 treatment regimens remained satisfactory. After 96 weeks of continuous treatment, HBV DNA suppression remained substantially greater with LdT compared to lamivudine. Mean 2-year serum HBV DNA reductions (log10 copies/ml) from pretreatment baseline were 5.2 for LdT vs 3.9 for lamivudine, and HBV DNA was nondetectable by COBAS PCR assay in 71% of LdT recipients vs 32 % of lamivudine recipients (p 0.05). ALT normalization at 2 yrs remained markedly greater for LdT recipients vs lamivudine recipients (81% vs 47%, p 0.05), and HBeAg seroconversion was higher for LdT recipients (38% vs 21%, p ns). Treatment failure (viral breakthrough with elevated ALT) was significantly lower for LdT vs lamivudine (4.5% vs. 21.1%, p 0.05). HBV DNA response in the first 6 months of treatment predicted longer-term efficacy outcomes at 2 years. As in the initial trial, in year 2 the combination regimen appeared proportionally better than lamivudine on all efficacy endpoints but was not better than LdT alone on any endpoint. Conclusions: Continuous telbivudine treatment for 2 years doubled the HBV DNA clearance rate and nearly doubled the ALT normalization rate compared to lamivudine, with proportionally greater HBeAg seroconversion and a much lower resistance-related treatment failure rate.
Persistent Identifierhttp://hdl.handle.net/10722/102878
ISSN
2015 Impact Factor: 18.187
2015 SCImago Journal Rankings: 7.170

 

DC FieldValueLanguage
dc.contributor.authorLai, CLen_HK
dc.contributor.authorLeung, NW-
dc.contributor.authorTeo, EK-
dc.contributor.authorTong, M-
dc.contributor.authorWong, F-
dc.contributor.authorHann, HWY-
dc.contributor.authorHan, SH-
dc.contributor.authorPoynard, T-
dc.contributor.authorQiao, X-
dc.contributor.authorPietropaolo, K-
dc.contributor.authorLloyd, D-
dc.contributor.authorBrown, NA-
dc.date.accessioned2010-09-25T20:48:30Z-
dc.date.available2010-09-25T20:48:30Z-
dc.date.issued2005en_HK
dc.identifier.citationDigestive Disease Week, Chicago, IL, 14-19 May 2005. In Gastroenterology, 2005, v. 128 n. 4 S2, p. A-692-
dc.identifier.issn0016-5085-
dc.identifier.urihttp://hdl.handle.net/10722/102878-
dc.description.abstractBackground: In a 1-year Phase IIb trial, telbivudine (LdT) treatment produced significantly greater antiviral effects and ALT normalization than standard lamivudine monotherapy in HBeAg-positive patients with chronic hepatitis B (Lai AASLD2003). The present follow-on study was designed to gain longer-term data on the comparative efficacy and safety of LdT vs lamivudine in patients who completed the previous trial. Methods: Patients (pts) completing the earlier trial were offered continuing treatment according to their previous treatment type: (a) pts previously treated with lamivudine continued on lamivudine (100 mg/d); (b) pts previously treated with LdT monotherapy (400 or 600 mg/d) continued on LdT 600 mg/d; and (c) pts previously treated with a combination treatment (LdT 400 or 600 mg/d plus lamivudine) continued on combination treatment (LdT 600 mg/d plus lamivudine 100 mg/d). Here we report efficacy and safety observations after 1 year of additional treatment, comprising 2 years of continuous treatment with these 3 types of anti-HBV treatment. Results: 90 of 99 pts (90%) who completed the previous study enrolled in this extension study. Overall tolerance of all 3 treatment regimens remained satisfactory. After 96 weeks of continuous treatment, HBV DNA suppression remained substantially greater with LdT compared to lamivudine. Mean 2-year serum HBV DNA reductions (log10 copies/ml) from pretreatment baseline were 5.2 for LdT vs 3.9 for lamivudine, and HBV DNA was nondetectable by COBAS PCR assay in 71% of LdT recipients vs 32 % of lamivudine recipients (p 0.05). ALT normalization at 2 yrs remained markedly greater for LdT recipients vs lamivudine recipients (81% vs 47%, p 0.05), and HBeAg seroconversion was higher for LdT recipients (38% vs 21%, p ns). Treatment failure (viral breakthrough with elevated ALT) was significantly lower for LdT vs lamivudine (4.5% vs. 21.1%, p 0.05). HBV DNA response in the first 6 months of treatment predicted longer-term efficacy outcomes at 2 years. As in the initial trial, in year 2 the combination regimen appeared proportionally better than lamivudine on all efficacy endpoints but was not better than LdT alone on any endpoint. Conclusions: Continuous telbivudine treatment for 2 years doubled the HBV DNA clearance rate and nearly doubled the ALT normalization rate compared to lamivudine, with proportionally greater HBeAg seroconversion and a much lower resistance-related treatment failure rate.-
dc.languageengen_HK
dc.publisherElsevier Inc.-
dc.relation.ispartofGastroenterologyen_HK
dc.titlePhase Iib Extended-Treatment Trial of Telbivudine (LdT) Vs Lamivudine Vs Combination Treatment in Hepatitis B Patients: Two-Year Resultsen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1053/j.gastro.2005.04.003-
dc.identifier.hkuros101828en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats